Literature DB >> 9862079

Opioid discrimination in humans: discriminative and subjective effects of progressively lower training dose.

K L Preston1, G E Bigelow.   

Abstract

The purpose of this study was to examine the extent of covariation of subjective and discriminative drug effects as the dose of the discriminated training drug was progressively lowered. Six adult male volunteers with histories of opioid abuse, who were not currently physically dependent, were trained to discriminate the mu-receptor agonist hydromorphone (20 mg, oral) from placebo in daily sessions. They received financial reinforcement for correct responses. The hydromorphone training dose was then progressively reduced (20, 14, 10, 7, 5, and 3.5 mg) while the discrimination reinforcement contingencies remained in effect. Measures of subjective and physiological effects were concurrently collected during each discrimination session. As the training dose decreased, discriminative performance was generally well maintained, although the percent of drug-appropriate responses to hydromorphone did decline from 98% to 75%. The magnitude of the subjective and physiological effects of hydromorphone also decreased as the training dose decreased. At the lowest training dose, there were no physiological effects and few subjective effects of hydromorphone statistically different from placebo, although discrimination behavior remained statistically significant at all doses. These data indicate covariation of subjective effects and discrimination performance and suggest that discrimination behavior may be more sensitive for differentiating among drug conditions than traditional subjective effects measures.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9862079     DOI: 10.1097/00008877-199811000-00009

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  9 in total

Review 1.  Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Curr Top Behav Neurosci       Date:  2018

2.  Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.

Authors:  Sharon L Walsh; Paul A Nuzzo; Shanna Babalonis; Victoria Casselton; Michelle R Lofwall
Journal:  Drug Alcohol Depend       Date:  2016-03-14       Impact factor: 4.492

3.  Assessing Discrimination of Nicotine in Humans Via Cigarette Smoking.

Authors:  Kenneth A Perkins; Nicole Kunkle; Valerie C Michael; Joshua L Karelitz; Eric C Donny
Journal:  Nicotine Tob Res       Date:  2016-03-24       Impact factor: 4.244

4.  Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.

Authors:  Michelle R Lofwall; Shanna Babalonis; Paul A Nuzzo; Samy Claude Elayi; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2016-05-10       Impact factor: 4.492

Review 5.  Role of training dose in drug discrimination: a review.

Authors:  Ian P Stolerman; Emma Childs; Matthew M Ford; Kathleen A Grant
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

6.  Effects of repeated oxycodone administration on its analgesic and subjective effects in normal, healthy volunteers.

Authors:  Ziva D Cooper; Maria A Sullivan; Suzanne K Vosburg; Jeanne M Manubay; Margaret Haney; Richard W Foltin; Suzette M Evans; William J Kowalczyk; Phillip A Saccone; Sandra D Comer
Journal:  Behav Pharmacol       Date:  2012-06       Impact factor: 2.293

7.  Measurement of the lowest dosage of phenobarbital that can produce drug discrimination in rats.

Authors:  Donald A Overton; Gregg D Stanwood; Bhavesh N Patel; Sreenivasa R Pragada; M Kathleen Gordon
Journal:  Psychopharmacology (Berl)       Date:  2008-12-13       Impact factor: 4.530

8.  Threshold dose for discrimination of nicotine via cigarette smoking.

Authors:  Kenneth A Perkins; Nicole Kunkle; Joshua L Karelitz; Valerie C Michael; Eric C Donny
Journal:  Psychopharmacology (Berl)       Date:  2016-04-02       Impact factor: 4.530

9.  Antagonist-precipitated and discontinuation-induced withdrawal in morphine-dependent rhesus monkeys.

Authors:  G L Becker; L R Gerak; W Koek; C P France
Journal:  Psychopharmacology (Berl)       Date:  2008-08-23       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.